 Sameer Nath
Concepts (162)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiosurgery | 17 | 2019 | 318 | 3.110 |
Why?
| | Brain Neoplasms | 9 | 2018 | 1022 | 1.280 |
Why?
| | Prostatic Neoplasms | 6 | 2019 | 940 | 1.270 |
Why?
| | Lung Neoplasms | 11 | 2019 | 2220 | 1.060 |
Why?
| | Radiotherapy, Intensity-Modulated | 7 | 2019 | 128 | 0.930 |
Why?
| | Radiation Oncology | 3 | 2021 | 76 | 0.910 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 6 | 2019 | 968 | 0.770 |
Why?
| | Radiation Dosage | 3 | 2019 | 147 | 0.740 |
Why?
| | Chemoradiotherapy | 2 | 2019 | 200 | 0.720 |
Why?
| | Education, Nursing | 1 | 2021 | 79 | 0.710 |
Why?
| | Organs at Risk | 1 | 2019 | 31 | 0.700 |
Why?
| | Immunity, Cellular | 1 | 2019 | 270 | 0.610 |
Why?
| | Brachytherapy | 2 | 2017 | 103 | 0.600 |
Why?
| | Radiotherapy Dosage | 9 | 2017 | 245 | 0.500 |
Why?
| | Positron-Emission Tomography | 4 | 2018 | 298 | 0.500 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 1390 | 0.490 |
Why?
| | Mycosis Fungoides | 1 | 2014 | 62 | 0.470 |
Why?
| | Aged, 80 and over | 14 | 2019 | 6561 | 0.470 |
Why?
| | Kaplan-Meier Estimate | 5 | 2019 | 842 | 0.420 |
Why?
| | Aged | 23 | 2019 | 19657 | 0.420 |
Why?
| | Four-Dimensional Computed Tomography | 1 | 2011 | 27 | 0.400 |
Why?
| | Radiography, Interventional | 1 | 2011 | 113 | 0.370 |
Why?
| | Urogenital System | 1 | 2009 | 16 | 0.360 |
Why?
| | Particle Accelerators | 1 | 2009 | 9 | 0.360 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2015 | 900 | 0.350 |
Why?
| | Middle Aged | 18 | 2019 | 27617 | 0.340 |
Why?
| | Proportional Hazards Models | 3 | 2019 | 1125 | 0.340 |
Why?
| | Multivariate Analysis | 4 | 2019 | 1474 | 0.330 |
Why?
| | Radiation Injuries | 1 | 2009 | 131 | 0.330 |
Why?
| | Magnetic Resonance Imaging | 7 | 2018 | 3174 | 0.320 |
Why?
| | Follow-Up Studies | 11 | 2018 | 4596 | 0.310 |
Why?
| | Male | 24 | 2021 | 57801 | 0.310 |
Why?
| | Gastrointestinal Tract | 1 | 2009 | 175 | 0.300 |
Why?
| | Glioma | 1 | 2010 | 306 | 0.300 |
Why?
| | Skin Neoplasms | 1 | 2014 | 762 | 0.280 |
Why?
| | Radiation Pneumonitis | 2 | 2017 | 26 | 0.280 |
Why?
| | Small Cell Lung Carcinoma | 2 | 2018 | 83 | 0.280 |
Why?
| | Adult | 15 | 2021 | 31512 | 0.280 |
Why?
| | Uterine Cervical Neoplasms | 3 | 2013 | 216 | 0.250 |
Why?
| | Radiotherapy | 2 | 2017 | 187 | 0.250 |
Why?
| | Treatment Outcome | 10 | 2019 | 9342 | 0.240 |
Why?
| | Humans | 34 | 2021 | 118974 | 0.240 |
Why?
| | Female | 21 | 2021 | 61565 | 0.220 |
Why?
| | Cranial Irradiation | 3 | 2018 | 70 | 0.210 |
Why?
| | Retrospective Studies | 11 | 2019 | 12978 | 0.190 |
Why?
| | Multimodal Imaging | 2 | 2018 | 100 | 0.190 |
Why?
| | Radiotherapy, Computer-Assisted | 2 | 2010 | 12 | 0.190 |
Why?
| | Neoplasm Metastasis | 2 | 2019 | 544 | 0.180 |
Why?
| | Survival Analysis | 5 | 2018 | 1267 | 0.180 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2018 | 197 | 0.180 |
Why?
| | Brain | 2 | 2010 | 2490 | 0.170 |
Why?
| | Lymphopenia | 1 | 2019 | 48 | 0.170 |
Why?
| | Combined Modality Therapy | 2 | 2019 | 1166 | 0.170 |
Why?
| | Needs Assessment | 1 | 2021 | 327 | 0.170 |
Why?
| | Tumor Hypoxia | 1 | 2018 | 5 | 0.170 |
Why?
| | Leukocyte Count | 1 | 2019 | 305 | 0.170 |
Why?
| | Neutropenia | 1 | 2019 | 133 | 0.160 |
Why?
| | CTLA-4 Antigen | 1 | 2018 | 86 | 0.160 |
Why?
| | Circulating Tumor DNA | 1 | 2018 | 22 | 0.160 |
Why?
| | Immune System | 1 | 2019 | 181 | 0.160 |
Why?
| | Disease-Free Survival | 1 | 2019 | 649 | 0.150 |
Why?
| | Disease Progression | 3 | 2019 | 2490 | 0.150 |
Why?
| | Lymphocytes | 1 | 2019 | 347 | 0.150 |
Why?
| | Absorbable Implants | 1 | 2017 | 35 | 0.150 |
Why?
| | Neoplasm Staging | 6 | 2018 | 1223 | 0.150 |
Why?
| | Ultrasonography | 2 | 2018 | 716 | 0.150 |
Why?
| | Androgen Antagonists | 1 | 2017 | 70 | 0.150 |
Why?
| | Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2017 | 74 | 0.140 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2013 | 610 | 0.140 |
Why?
| | Prognosis | 5 | 2018 | 3443 | 0.140 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2017 | 360 | 0.140 |
Why?
| | Chi-Square Distribution | 1 | 2017 | 525 | 0.140 |
Why?
| | Propensity Score | 1 | 2017 | 242 | 0.140 |
Why?
| | Antibodies | 1 | 2018 | 392 | 0.140 |
Why?
| | United States | 6 | 2021 | 12555 | 0.130 |
Why?
| | Time Factors | 3 | 2018 | 6412 | 0.130 |
Why?
| | Heart | 1 | 2019 | 631 | 0.130 |
Why?
| | Neoadjuvant Therapy | 1 | 2017 | 333 | 0.130 |
Why?
| | Age Factors | 2 | 2014 | 2995 | 0.130 |
Why?
| | Tomography, X-Ray Computed | 4 | 2018 | 2436 | 0.130 |
Why?
| | Dose-Response Relationship, Radiation | 2 | 2018 | 129 | 0.130 |
Why?
| | Risk Factors | 4 | 2017 | 9000 | 0.120 |
Why?
| | Odds Ratio | 1 | 2017 | 996 | 0.120 |
Why?
| | Cisplatin | 2 | 2013 | 271 | 0.120 |
Why?
| | Treatment Failure | 2 | 2015 | 341 | 0.120 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 195 | 0.120 |
Why?
| | Marital Status | 1 | 2014 | 43 | 0.120 |
Why?
| | Clinical Competence | 1 | 2021 | 951 | 0.120 |
Why?
| | Neutrophils | 1 | 2019 | 1233 | 0.120 |
Why?
| | Young Adult | 5 | 2017 | 10793 | 0.120 |
Why?
| | Salvage Therapy | 2 | 2015 | 130 | 0.120 |
Why?
| | SEER Program | 1 | 2014 | 205 | 0.110 |
Why?
| | Databases, Factual | 1 | 2017 | 1231 | 0.110 |
Why?
| | Logistic Models | 1 | 2017 | 1901 | 0.100 |
Why?
| | Melanoma | 1 | 2018 | 664 | 0.100 |
Why?
| | Biomarkers, Tumor | 1 | 2018 | 1059 | 0.100 |
Why?
| | Practice Patterns, Physicians' | 2 | 2010 | 1200 | 0.100 |
Why?
| | Cervix Uteri | 1 | 2011 | 48 | 0.100 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2011 | 109 | 0.090 |
Why?
| | Cone-Beam Computed Tomography | 1 | 2009 | 28 | 0.090 |
Why?
| | Survival Rate | 4 | 2016 | 1720 | 0.090 |
Why?
| | Registries | 1 | 2017 | 1810 | 0.090 |
Why?
| | Cause of Death | 1 | 2011 | 380 | 0.090 |
Why?
| | Prostatectomy | 1 | 2009 | 100 | 0.090 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2009 | 189 | 0.090 |
Why?
| | Surveys and Questionnaires | 1 | 2021 | 4708 | 0.080 |
Why?
| | Tumor Burden | 1 | 2010 | 274 | 0.080 |
Why?
| | Postoperative Period | 1 | 2009 | 309 | 0.080 |
Why?
| | Sex Factors | 1 | 2014 | 1781 | 0.080 |
Why?
| | Healthcare Disparities | 1 | 2014 | 496 | 0.080 |
Why?
| | Neurosurgical Procedures | 1 | 2009 | 164 | 0.080 |
Why?
| | Image-Guided Biopsy | 2 | 2018 | 34 | 0.080 |
Why?
| | Imaging, Three-Dimensional | 1 | 2011 | 499 | 0.080 |
Why?
| | Incidence | 1 | 2014 | 2424 | 0.070 |
Why?
| | Neoplasm Grading | 2 | 2018 | 258 | 0.070 |
Why?
| | Diagnostic Imaging | 1 | 2009 | 294 | 0.070 |
Why?
| | Lung | 1 | 2019 | 3664 | 0.070 |
Why?
| | Comorbidity | 1 | 2011 | 1527 | 0.070 |
Why?
| | Head and Neck Neoplasms | 1 | 2011 | 471 | 0.070 |
Why?
| | Neoplasms | 2 | 2010 | 2179 | 0.070 |
Why?
| | Severity of Illness Index | 1 | 2009 | 2674 | 0.050 |
Why?
| | Physicians | 1 | 2009 | 794 | 0.050 |
Why?
| | Prospective Studies | 3 | 2018 | 6471 | 0.050 |
Why?
| | Automation | 1 | 2020 | 77 | 0.050 |
Why?
| | Patient Positioning | 1 | 2020 | 49 | 0.050 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 2 | 2011 | 120 | 0.040 |
Why?
| | False Positive Reactions | 1 | 2018 | 115 | 0.040 |
Why?
| | Statistics, Nonparametric | 1 | 2018 | 403 | 0.040 |
Why?
| | Child, Preschool | 1 | 2010 | 9491 | 0.040 |
Why?
| | B7-H1 Antigen | 1 | 2018 | 144 | 0.040 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2018 | 156 | 0.030 |
Why?
| | Radiometry | 1 | 2015 | 45 | 0.030 |
Why?
| | Risk Assessment | 2 | 2017 | 3057 | 0.030 |
Why?
| | Fibrosis | 1 | 2017 | 483 | 0.030 |
Why?
| | Radiology | 1 | 2017 | 199 | 0.030 |
Why?
| | Immunotherapy | 1 | 2018 | 493 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2018 | 1384 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2017 | 1795 | 0.030 |
Why?
| | Adolescent | 1 | 2010 | 18480 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2513 | 0.020 |
Why?
| | Child | 1 | 2010 | 19129 | 0.020 |
Why?
| | Decision Making | 1 | 2017 | 809 | 0.020 |
Why?
| | Vinblastine | 1 | 2010 | 68 | 0.020 |
Why?
| | Motion | 1 | 2011 | 95 | 0.020 |
Why?
| | Radiographic Image Enhancement | 1 | 2010 | 65 | 0.020 |
Why?
| | Algorithms | 1 | 2017 | 1541 | 0.020 |
Why?
| | Carboplatin | 1 | 2010 | 142 | 0.020 |
Why?
| | Utilization Review | 1 | 2009 | 36 | 0.020 |
Why?
| | Tomography Scanners, X-Ray Computed | 1 | 2009 | 18 | 0.020 |
Why?
| | Fluorouracil | 1 | 2010 | 151 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2010 | 324 | 0.020 |
Why?
| | Hysterectomy | 1 | 2010 | 117 | 0.020 |
Why?
| | Rectum | 1 | 2010 | 157 | 0.020 |
Why?
| | Urinary Bladder | 1 | 2010 | 180 | 0.020 |
Why?
| | Health Care Surveys | 1 | 2010 | 546 | 0.020 |
Why?
| | Cohort Studies | 1 | 2018 | 5116 | 0.020 |
Why?
| | Equipment Design | 1 | 2009 | 519 | 0.020 |
Why?
| | Mutation | 1 | 2018 | 3457 | 0.020 |
Why?
| | Radiography | 1 | 2009 | 861 | 0.020 |
Why?
| | Data Collection | 1 | 2009 | 658 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2013 | 3171 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 2010 | 1974 | 0.010 |
Why?
|
|
Nath's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|